This chapter gives some examples of the risk of developing or transmitting a mendelian disorder. The mathematical risk calculated from data on a pedigree may often be modied by additional information from specific tests to detect carriers. Risk can be expressed as either a percentage or a fraction.
Autosomal dominant disorders The 50% risk of developing a condition for the offspring of an affected person may be modified by age in disorders whose onset is in adult life, such as Huntington's chorea. In examples 1 and 2 the risk to person B of developing Huntington's chorea is still 50% at age 30 years, but by the age of 65 the residual risk to a healthy person has fallen to 10%. The risk to person C therefore falls from 25% in example 1 to 5% in example 2. In example 3 the risk for C cannot be reduced below 25% because parent B, although clinically unaffected, died aged 30 while still at 50% risk.
When both parents have the same autosomal dominant disorder, the risk to the offspring will be high (example 4). Only one in four children will be unaffected, and one in four will be homozygous for the mutant gene, which may cause severe disease, as in familial hypercholesterolaemia or achondroplasia. In lethal X linked disorders new mutations account for a third of all cases. A mother of an affected boy is therefore not always a carrier. Carrier risks in families in which there is an isolated case of such a disorder (for example, Duchenne muscular dystrophy) are shown in example 14. These risks would again be modified by the presence of any unaffected males in the pedigree as well as by the results of specific tests to detect carriers. Glucocorticoids have complex effects on calcium and skeletal metabolism. Their administration in pharmacological amounts induces an acute increase in the urinary excretion of calcium. At the onset of their administration this may be partly related to a transient stimulation of intestinal calcium absorption, but calcium absorption is subsequently reduced and calciuria is principally due to the catabolic effects of corticosteroids on bone. Bone loss is rapid in the first few years of corticosteroid use, and thereafter the rate of loss falls as does the urinary excretion of calcium. The aetiology of calcium nephrolithiasis is also complex and multifactorial. The risk of renal stones increases progressively with increasing rates of excretion of calcium,' and thus giving exogenous steroids presumably increases this risk. The older textbooks claim that renal stones occur in about a fifth of patients with longstanding Cushing's syndrome,2 but renal stones in some of these cases may have been due to multiple endocrine neoplasia (with hyperparathyroidism Has resistance been reported to multiple drug treatment for leprosy with rifampicin, clofazimine, and dapsone? Ifso, how is drug resistance measured?
There have been no published reports of resistance to the multiple drug treatment recommended since 1982 by the World Health Organisation (WHO) for leprosy, a treatment that is rapidly becoming universally accepted. Though drug resistance is unlikely after such a powerful antileprosy triple treatment, drug resistance in leprosy can be measured only clinically in view of the impracticability of routinely using mouse footpad infection as a direct measure of drug resistance of Mycobactenium leprae.
Drug resistance in leprosy is diagnosed as the cause of relapse or failure to improve after the standard WHO course of multiple drug treatment only when it can be confirmed beyond reasonable doubt that the drug dose and duration and regularity of treatment have been adhered to. The following criteria must be satisfied before drug resistance can be considered the cause of failure of multiple drug treatment in leprosy: (1) monthly attendance records to confirm attendance of the patient for supervised dose of rifampicin and topping up dose of clofazimine; (2) orange/red coloration of a urine sample taken between two and 10 hours after supervised dose of rifampicin; (3) reddish coloration of the skin within two to three months of the start of treatment confirms self administration of clofazimine; and (4) random urine tests for quantitative assessment of dapsone concentrations to confirm regular self administration of dapsone. -R J W REES, research consultant, London
